PMEF
REGN icon

Point72 Middle East FZE’s Regeneron Pharmaceuticals REGN Stock Holding History

Point72 Middle East FZE’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-200
Closed -$176K – 1051
2023
Q4 		$176K Sell
200
-1,200
-86% -$988K 0.01% 1076
2023
Q3 		$1.15M Buy
1,400
+900
+180% +$707K 0.04% 529
2023
Q2 		$359K Sell
500
-1,700
-77% -$1.31M 0.01% 870
2023
Q1 		$1.81M Sell
2,200
-100
-4% -$75.4K 0.06% 353
2022
Q4 		$1.66M Buy
+2,300
New +$1.7M 0.07% 354

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Point72 Middle East FZE's REGN Position: Q1 2024 in Review

Point72 Middle East FZE sold out of Regeneron Pharmaceuticals (REGN) in Q1 2024, closing a stake of 3,440 shares — an estimated $3.02M sold.

Point72 Middle East FZE first reported a position in REGN in Q4 2022 and held it in 4 quarters. The position peaked at $11.3M in Q4 2022. 1,310 funds tracked by Wall St. Rank hold REGN as of Q1 2024.

  • Point72 Middle East FZE reported no remaining Regeneron Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Point72 Middle East FZE sold 3,440 Regeneron Pharmaceuticals shares in Q1 2024, an estimated $3.02M.
  • Point72 Middle East FZE first reported a position in Regeneron Pharmaceuticals in Q4 2022 and held it in 4 quarters.
  • Point72 Middle East FZE's Regeneron Pharmaceuticals position peaked at $11.3M in Q4 2022.
  • 1,310 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.